Asia-Pacific Computed Tomography (CT) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Asia-Pacific computed tomography (CT) market size in 2026 is estimated at USD 2.62 billion, growing from 2025 value of USD 2.47 billion with 2031 projections showing USD 3.53 billion, growing at 6.12% CAGR over 2026-2031. This report is Segmented by Technology (Low, Medium, High, Cone-Beam CT), Application (Oncology, Cardiology, Neurology, Musculoskeletal, Others), End-User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgery Centers, Others), Product Type (Stationary CT, Portable CT), and Geography (China, India, Japan, and More). The Market Forecasts are Provided in Terms of Value (USD).

Asia-Pacific Computed Tomography (CT) Market Trends and Insights

Aging Population & Chronic-Disease Burden Surge

Rising life expectancy in Japan, South Korea, and urban China is shifting the disease profile toward oncology, cardiovascular, and neurodegenerative disorders that depend on cross-sectional imaging for diagnosis and treatment monitoring. National cancer-screening campaigns have broadened CT access in secondary cities, while diabetes-related vascular complications are increasing abdominal and peripheral CT angiography studies in India. Radiology departments therefore budget for higher-performance scanners that permit multi-phase protocols within a single breath-hold and deliver thin-slice reconstructions suitable for AI decision-support tools. Dose-optimization guidance from Australia’s ARPANSA is also influencing protocol standardization across the region, reinforcing the need for detector advancements and iterative reconstruction engines that can maintain image quality while lowering patient exposure.

Government Imaging-Equipment Subsidy Programs (China, India)

China’s “Made in China” procurement directive links public-tender eligibility to local manufacturing, favoring domestic vendors that package scanners with multi-year service contracts and staff training. India’s Production-Linked Incentive scheme offers a 20% capital subsidy on CT-scanner components and retains a 5% concessional customs duty on X-ray tubes through March 2025, reducing total landed cost for assemblers. These initiatives compress payback periods for hospitals and drive cluster-based manufacturing investments that shorten lead times for export customers in Southeast Asia.

High Service-Contract & X-Ray-Tube Replacement Costs

Annual service fees range from USD 42,000 for entry-level systems to more than USD 100,000 for ≥64-slice models, an outlay that many mid-size hospitals struggle to recoup under fixed patient tariffs. Tube failure remains the single largest unplanned cost; a replacement assembly for a 64-slice platform typically lists above USD 100,000. Some hospitals negotiate risk-sharing service plans that cap downtime penalties, yet others postpone upgrades altogether, stimulating a refurbished-scanner channel that offers 30-50% up-front savings.

Other drivers and restraints analyzed in the detailed report include:

• Hospital Upgrade Cycle from 16/32-Slice to ≥64-Slice Systems
• Surge in Cardiac CT Angiography Post-2024 Guideline Changes
• Uneven Reimbursement Outside Tier-1 APAC Cities

Segment Analysis

Mid-range 64-slice scanners held 48.62% of the Asia-Pacific Computed Tomography (CT) market in 2025, reflecting broad compatibility with oncology, trauma, and pulmonary indications. Hospitals regard this class as the baseline for forward compatibility with cardiac workflows, balancing capex against insurance coverage thresholds. Photon-counting and other spectral platforms are forecast at a 7.02% CAGR to 2031 as Japan and Singapore validate superior calcium-scoring reproducibility and dose reductions of up to 40%. Early adopters leverage OEM trade-in credits to temper the premium, repurposing outgoing scanners into satellite clinics. At the opposite end, sub-64-slice systems lose share each year because government tenders in China and Malaysia now stipulate ≥64-slice capability as a minimum eligibility criterion. High-slice (≥128) configurations fill a premium niche in pediatric and cardiovascular centers where wide detector arrays shorten breath-hold times and mitigate motion artifacts; their installed base is expanding 5-6 percentage points per annum in tertiary facilities.

Trading dynamics revolve around bundled AI software that automates bone subtraction, lung-nodule quantification, and metal-artifact reduction. These features prolong the useful life of mid-end scanners and ease the transition toward spectral imaging by offering incremental clinical value without immediate detector upgrades. OEMs also position subscription-based algorithm libraries that transform conventional 64-slice hardware into provisional dual-energy systems, preserving account loyalty ahead of full photon-counting conversion.

Oncology maintained the largest share at 35.31% in 2025, buoyed by lung-cancer screening mandates in China and rising PET-CT hybrid referrals that necessitate complementary contrast CT. Routine staging protocols, encompassing chest, abdomen, and pelvis, keep utilization rates high even in resource-limited settings. Still, cardiology is the fastest-growing vertical at a 7.28% CAGR, propelled by guideline-endorsed CT angiography and widening reimbursement for calcium scoring packages. Hospitals now seek scanners capable of single-beat whole-heart coverage, integrated ECG gating, and AI-driven stenosis quantification. These technical requirements narrow vendor options and elevate the average deal size, increasing overall revenue contribution from cardiac imaging despite its smaller case volume. Neurology benefits from portable CT installations in mobile stroke units, aligning with regional pre-hospital care initiatives that prioritize rapid door-to-needle times. Musculoskeletal imaging maintains steady demand in sports-medicine clinics across Australia and South Korea, leveraging low-dose protocols that safeguard pediatric and athlete cohorts.

Growing subspecialization drives hospitals to negotiate multi-scanner packages that allocate oncology workloads to 64-slice rooms while reserving spectral or photon-counting suites for coronary and perfusion studies. This case-mix optimization maximizes scanner throughput and accelerates return on investment. Software ecosystems further segment applications; for example, AI-based lung-nodule follow-up modules secure oncology revenue streams, whereas plaque-quantification suites capture cardiology workflows, fostering brand lock-in.

Complete Report Scope:

• By Technology (Slice Count) - Value
  • Low (< 64)
  • Medium (64)
  • High (≥128)
  • Cone-Beam CT
• By Application - Value
  • Oncology
  • Cardiology
  • Neurology
  • Musculoskeletal
  • Others
• By End-User - Value
  • Hospitals
  • Diagnostic Imaging Centers
  • Ambulatory Surgery Centers
  • Others
• By Product Type - Value
  • Stationary CT
  • Portable CT
• By Country - Value
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Rest of Asia-Pacific

List of Companies Covered in this Report:

• Animage, LLC
• Canon
• Carestream Health
• CurveBeam AI, Inc.
• Epica Medical Innovations
• FUJIFILM
• GE HealthCare Technologies Inc.
• Koninklijke Philips
• MARS Bioimaging Ltd.
• Neusoft
• Planmeca
• Samsung Group
• Shenzhen Anke High-Tech Co., Ltd.
• Siemens Healthineers
• United Imaging Healthcare Co., Ltd.
• Xoran Technologies, LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support